1 / 42

Personalizing Chemotherapy for Patients With Metastatic Breast Cancer

Personalizing Chemotherapy for Patients With Metastatic Breast Cancer. Program Goal. Outline. Therapeutic Goals. Phase 3 Clinical Trials With Overall Survival as an End Point. FDA Criteria for Approval of Oncology Drugs for Metastatic Breast Cancer.

quintana-topaz
Télécharger la présentation

Personalizing Chemotherapy for Patients With Metastatic Breast Cancer

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Personalizing Chemotherapy for Patients With Metastatic Breast Cancer

  2. Program Goal

  3. Outline

  4. Therapeutic Goals

  5. Phase 3 Clinical Trials With Overall Survival as an End Point

  6. FDA Criteria for Approval of Oncology Drugs for Metastatic Breast Cancer

  7. Survival and FDA Approval of Oncology Drugs for Metastatic Breast Cancer

  8. Drug Approvals for Metastatic Breast Cancer

  9. Toxicities Associated With Approved Therapies

  10. Sources of Antitubulins

  11. Tubulin and Microtubules

  12. Function of Microtubules

  13. Structure-Activity Relationship to Taxanes

  14. Trials Comparing Agents With Paclitaxel 175 mg/m2 Every 3 Weeks

  15. Role of Albumin in Nab-Paclitaxel

  16. Phase 3 Trial: Standard Paclitaxel vs Nab-Paclitaxel

  17. Phase 3 Trials of Capecitabine With or Without Ixabepilone in Pretreated Advanced Breast Cancer

  18. Results of Phase 3 Trials of Capecitabine With or Without Ixabepilone

  19. Toxicities in Phase 3 Trials of Capecitabine With or Without Ixabepilone

  20. Capecitabine With or Without Ixabepilone in Triple-Negative MBC

  21. E2100: Paclitaxel With or Without Bevacizumab as First-Line Therapy in MBC

  22. CALGB 40502 Trial Design

  23. CALGB 40502: Progression-Free Survival By Treatment Arm

  24. Dose Modifications by Treatment

  25. EMBRACE Trial Design

  26. Patient Characteristics

  27. Treatment of Physician’s Choice Received

  28. Progression-Free Survival

  29. Grades 3 and 4 Adverse Events

  30. Eribulin Study 301

  31. Overall Survival

  32. Overall Survival By Receptor Status

  33. Cytotoxic Therapy for Metastatic Breast Cancer: Summary

  34. Abbreviations

  35. Abbreviations (cont)

  36. References

  37. References (cont)

  38. References (cont)

  39. References (cont)

  40. References (cont)

  41. References (cont)

More Related